Transcriptomics profiling of Parkinson’s disease progression subtypes reveals distinctive patterns of gene expression
This study provides novel information regarding the transcriptomics profiles of PD progression subtypes, which may foster precision medicine with relevant indications for a finer-grained diagnosis and prognosis.
Authors
- Carlo Fabrizio (ORCID: https://orcid.org/0000-0002-7824-8423)
- Carlo Caltagirone (ORCID: https://orcid.org/0000-0002-0189-4515)
- Andrea Termine (ORCID: https://orcid.org/0000-0003-4374-7430)
Institutions
- Fondazione Santa Lucia (IT)
Publication Details
- Journal
- Journal of Central Nervous System Disease
- Published
- 2025-01-27
- DOI
- https://doi.org/10.1177/11795735241286821
- Citations
- 2
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.78
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Celgene
- Neurocrine Biosciences
- Verily Life Sciences
- Voyager Therapeutics
- Ministero della Salute
- Servier
- H. Lundbeck A/S
- Sun Pharma
- Genentech
- Allergan
- Avid Radiopharmaceuticals